Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020

August 2020 | 163 pages | ID: IE26D2E4EE7EN
Global Markets Direct

Abstracts

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 6, 2, 18 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 4 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Influenza A Virus, H3N2 Subtype Infections - Overview
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Alla Chem LLC, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020 (Contd..2), H2 2020
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

AbbVie Inc
Adimmune Corp
Alla Chem LLC
Allergy Therapeutics Plc
Ansun Biopharma Inc
Aphios Corp
AstraZeneca Plc
AusBio Ltd
BiondVax Pharmaceuticals Ltd
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
Changchun Bcht Biotechnology Co Ltd
Chicago Biosolutions Inc
Cidara Therapeutics Inc
ContraFect Corp
Emergent BioSolutions Inc
FluGen Inc
Gamma Vaccines Pty Ltd
i2 Pharmaceuticals Inc
ILiAD Biotechnologies LLC
Inovio Pharmaceuticals Inc
InvVax Inc
Jiangsu Ab&b Biotechnology Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Medicago Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Novavax Inc
PrEP Biopharm Ltd
Sanofi
Sciogen Inc
Seqirus Ltd
Serum Institute of India Ltd
Vacthera BioTech GmbH